Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054215 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL29697165 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1053924 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL9345489 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL19390430 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14372163 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14747283 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14747281 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL9838648 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL15721071 | 0.95 | CA1 (0.46) | CA1CA2CA7CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626460-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | The University of Queensland (AU) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | SIMON FRASER UNIVERSITY (CA) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | CA1 148/4885CA2 216/4885CA7 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.